In this episode of the Molecule to Market podcast, NorthX Biologics CEO Janet Hoogstraate was invited to discuss the implications of integrating Catalent’s capabilities into Novo Nordisk’s operations and what it means for the broader CDMO sector, in a panel together with other industry experts:
Dirk Lange, CEO at Pyramid Labs
Brett Alderson, President & Site Leader at NovaCina
John Cameron, Director, Global Injectables Platform at Corden Pharma
Podcast host Raman Sehgal discusses the pharmaceutical and biotechnology supply chain with Dirk, Brett, John & Janet, focusing on:
Maximizing GLP-1 manufacturing capacity: Discussing Novo Nordisk’s recent acquisition of Catalent’s manufacturing facilities to bolster GLP-1 production capabilities
Industry consolidation: What this acquisition means for the pharmaceutical outsourcing industry and its impact on competition among CDMOs
Meeting surging demand: Exploring how this move positions Novo Nordisk to respond to the rapidly increasing demand for GLP-1 receptor agonists, like those used in diabetes and obesity treatments
Strategic manufacturing: The implications of integrating Catalent’s capabilities into Novo Nordisk’s operations and what it means for the broader CDMO sector
With GLP-1 drugs at the forefront of diabetes and obesity treatment, Novo Nordisk’s strategic acquisition of Catalent aims to strengthen its supply chain and boost production capacity to meet global demand. Our guests provide in-depth insights into how this acquisition could shape the future of drug development and outsourcing across the industry.
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
NorthX Biologics is a CDMO and Innovation Hub in Advanced Biologics, with +30 years of GMP production experience. The team provides process development and GMP manufacturing services with expertise in plasmid DNA, mRNA, proteins, cells and other advanced biologics. Headquartered in the heart of Sweden, the team serves customers worldwide and in 2021 was recognized as a national innovation hub for advanced therapeutics and vaccines. NorthX Biologics has the ambition to become a leading cell and gene therapy manufacturer and partner of choice for innovative drug development companies.
Janet Hoogstraate, CEO of NorthX Biologics, recently appeared in an episode of BEYOND TOMORROW, a podcast by Plantvision. Janet discusses challenges and opportunities within Swedish pharmaceutical manufacturing, with a special focus on ...
Outer membrane vesicles (OMVs) and extracellular vesicles (EVs) are revolutionizing biopharmaceuticals, offering cutting-edge vaccines and therapeutic delivery solutions. These nanoscale vesicles hold immense potential to enhance immune responses and serve ...
Neoantigen cancer vaccines represent a groundbreaking advancement in personalized medicine, offering tailored cancer treatments designed for each patient’s unique tumor profile. These therapies require rapid turnaround from tumor identification to ...